Broker Tips
Investec's Ian Gordon downgrades StanChart to 'sell'
Analysts at Investec took their recommendation on shares of StanChart down from 'hold' to 'sell', telling clients the outlook for earnings per share and return on capital are now less convincing.
Broker tips: StanChart, Hikma Pharmaceuticals, BT Group
Analysts at Investec took their recommendation on shares of StanChart down from 'hold' to 'sell', telling clients the outlook for earnings per share and return on capital are now less convincing.
RBC trims BT Group target price
Analysts at RBC sounded a fairly upbeat note on BT Group despite the multiple calls on its cash which the company is expected to face over the next couple of years.
JP Morgan slashes target price on Hikma Pharmaceuticals
JP Morgan slashed its target price on stock of Hikma Pharmaceuticals saying US regulatory approval of its generic Advair application might be postponed, which in turn made the investment bank less confident on the firm's entire drug pipeline.
Friday broker round-up
Standard Chartered: Investec downgrades to Sell with a target price of 690p.